{"id":208246,"name":"SUMITOMO PHARMA AMERICA, INC.","slug":"sumitomo-pharma-america-inc","state":"MA","country":"United States of America","description":"pharmaceutical company","totalSpending":550000,"filings":13,"yearlySpending":[{"year":2021,"income":20000},{"year":2022,"income":200000},{"year":2023,"income":260000},{"year":2024,"income":70000}],"issues":["HCR","MMM"],"firms":["IMPACT HEALTH POLICY PARTNERS"],"lobbyists":["BILLY WYNNE","ALYSON LEWIS"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Health & Human Services, Dept of (HHS)","White House Office"],"sampleDescriptions":["Issues relating to Medicare Part D reform, mental health, central nervous system disorders, and Parkinsons Disease.","Issues relating to Medicare Part D reform, mental health, central nervous system disorders, and Parkinsons Disease.","Phase-in of Part D reform for low-income subsidy beneficiaries; H.R.5376, Build Back Better Act.","Phase-in of Part D reform for low-income subsidy beneficiaries; H.R.5376, Build Back Better Act.","Phase-in of Part D reform for low-income subsidy beneficiaries; H.R. 5376, FY 2022 Budget Reconciliation; and H.R.2471, Consolidated Appropriations Act, 2022 (P.L. 117-103)."],"years":[2021,2022,2023,2024]}